The federal government has weighed in on a whistleblower suit accusing Bayer Corp. of paying kickbacks to get doctors to use a surgery drug called Trasylol, saying the company can still be held liable under the False Claims Act even though the government pays for the drugs as part of a bundle rather than individually.
A New Jersey federal judge declined Monday to reconsider his order allowing two False Claims Act claims in a whistleblower's long-running suit against Bayer Corp. for allegedly pushing off-label uses of heart surgery drug Trasylol.
A New Jersey federal judge has agreed to review recent decisions supporting arguments that Bayer Pharmaceutical Corp. should repay the government for allegedly off-label marketed drugs in a whistleblower False Claims Act suit he largely dismissed last year due to ambiguity over whether the government can recoup the funds.
A New Jersey federal judge on Tuesday declined to reconsider the dismissal of much of a long-running employee whistleblower False Claims Act suit against Bayer Corp., saying the company is not required to repay the government for drugs it marketed off-label and those for which it received reimbursements.
A New Jersey federal judge on Friday cut down a long-running employee whistleblower suit accusing Bayer Corp. of fleecing government health programs by pushing off-label uses of heart-surgery drug Trasylol and breaching anti-kickback law, ruling that violations of federal misbranding law alone are insufficient to trigger False Claims Act liability.
A New Jersey federal judge on Friday narrowed a Bayer Corp. whistleblower’s suit over alleged False Claims Act infractions tied to two drugs, tossing claims for violative off-label marketing but not for breaches of federal anti-kickback law.
A New Jersey federal judge on Tuesday separated a consolidated false claims whistleblower lawsuit over allegations Bayer AG wrongly promoted off-label uses for its heart surgery drug Trasylol, saying the two relators can't proceed together.